Tumor Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy
Report Highlights
This report will assess the latest developments that are taking place with regard to the current research and development environment of TILs and explore the novel strategies companies are adopting to identify and enhance TIL selection, biosynthesis and delivery in a wide range of metastatic cancers including, melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors.
Report Includes
- 肿瘤浸润淋巴细胞（TIL）的概述用于治疗转移性癌症
- Discussion of the development of TIL as a treatment option for melanoma and the possibilities to expand this therapy to other types of cancer
- 使用抗原特异性CD8+ T细胞克隆来探索过养T细胞疗法（ATCT），以治疗转移性黑色素瘤患者，以及在各种其他实体瘤中ATCT的治疗潜力
- 肿瘤免疫疗法的两种主要技术，嵌合抗体受体工程T细胞（CAR-T）与转基因T细胞受体（TCR）之间的比较
- Information on the role of TILs as a strong prognostic biomarker for triple-negative breast cancer (TNBC) and their potential ramifications
Analyst Credentials
Dr. C.L. Barton has more than 10 years’ practical pharmaceutical research experience with a leading pharmaceutical company and has served as a Pan-European Pharmaceutical analyst with a European bank. Dr. C.L. Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Research reports combine independent scientific analysis with patient- and prescription-based models to forecast the potential sales growth of key developmental drugs and to isolate the key drivers within the pharmaceutical sector. For further information, visit www.pharmavision.co.uk.
Bianca Piachaud-Moustakis博士拥有15年以上的作家和研究分析师，专门从事药品和医疗保健情报，并为英国的许多市场情报提供商工作。她拥有广泛的写作经验，从国际学术和从业者期刊到制作市场情报报告和简短文章。专业领域包括药品，医疗保健，诊断，药物输送系统，新兴的研发技术和药品调节。